CERRATO, ANIELLO
CERRATO, ANIELLO
Istituto di Endocrinologia e Oncologia Sperimentale ''G. Salvatore'' - IEOS
Editorial: Combinatorial Approaches for Cancer Treatment: From Basic to Translational Research
2022 Aniello Cerrato; George Mattheolabakis; Daniela Spano
Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma
2019 Morra, F; Merolla, F; D'Abbiero, D; Ilardi, G; Campione, S; Monaco, R; Guggino, G; Ambrosio, F; Staibano, S; Cerrato, A; Visconti, R; Celetti, A
CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis 06 Biological Sciences 0601 Biochemistry and Cell Biology
2019 Morra F.; Merolla F.; Criscuolo D.; Insabato L.; Giannella R.; Ilardi G.; Cerrato A.; Visconti R.; Staibano S.; Celetti A.
Identification of novel biomarkers of homologous recombination defect in DNA repair to predict sensitivity of prostate cancer cells to PARP-inhibitors
2019 Criscuolo D.; Morra F.; Giannella R.; Cerrato A.; Celetti A.
New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment
2019 Criscuolo D.; Morra F.; Giannella R.; Visconti R.; Cerrato A.; Celetti A.
NSCLC Mutated Isoforms of CCDC6 Affect the Intracellular Distribution of the Wild Type Protein Promoting Cisplatinum Resistance and PARP Inhibitors Sensitivity in Lung Cancer Cells.
2019 Cerrato A; Morra F; Di Domenico I; Celetti A.
The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer
2018 Cerrato, Aniello; Visconti, Roberta; Celetti, Angela
CCDC6: The identity of a protein known to be partner in fusion
2017 Cerrato A.; Merolla F.; Morra F.; Celetti A.
The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells.
2017 Morra, Francesco; Merolla, Francesco; Napolitano, Virginia; Ilardi, Gennaro; Miro, Caterina; Paladino, Simona; Staibano, Stefania; Cerrato, Aniello; Celetti, Angela
USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs
2017 Malapelle U.; Morra F.; Ilardi G.; Visconti R.; Merolla F.; Cerrato A.; Napolitano V.; Monaco R.; Guggino G.; Monaco G.; Staibano S.; Troncone G.; Celetti A.
Wnt/Tcf1 pathway restricts embryonic stem cell cycle through activation of the Ink4/Arf locus
2017 De JaimeSoguero, A; Aulicino, F; Ertaylan, G; Griego, A; Cerrato, A; Tallam, A; del Sol, A; Cosma, Mp; Lluis, F
Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: The rationale for their inclusion in the clinic
2016 Cerrato, A; Morra, F; Celetti, A
FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC.
2015 Morra, F; Luise, C; Merolla, F; Poser, I; Visconti, R; Inuzuka, H; Ilardi, G; Guggino, G; Monaco, R; Colecchia, D; Monaco, G; Cerrato, A; Chiariello, M; Denning, Krista; Paolo Claudio, Pier; Staibano, S; Celetti, A
New therapeutic perspectives in CCDC6 deficient lung cancer cells
2015 Morra F.; Luise C.; Visconti R.; Staibano S.; Merolla F.; Ilardi G.; Guggino G.; Paladino S.; Sarnataro D.; Franco R.; Monaco R.; Zitomarino F.; Pacelli R.; Monaco G.; Rocco G.; Cerrato A.; Linardopoulos S.; Muller M.T.; Celetti A.
New therapeutic perspectives in CCDC6 deficient lung cancer cells.
2014 Morra F; Luise C; Visconti R; Staibano S; Merolla F; Ilardi G; Guggino G; Paladino S; Sarnataro D; Franco R; Monaco R; Zitomarino F; Pacelli R; Monaco G; Rocco G; Cerrato A; Linardopoulos S; Muller MT; Celetti A.
Chromatin and DNA methylation dynamics during retinoic acid-induced RET gene transcriptional activation in neuroblastoma cells.
2011 Angrisano, T; Sacchetti, S; Natale, F; Cerrato, A; Pero, R; Keller, S; Peluso, S; Perillo, B; Avvedimento, Ve; Fusco, A; Bruni, Cb; Lembo, F; Santoro, M; Chiariotti, L
CCDC6 represses CREB1 activity by recruiting histone deacetylase 1 and protein phosphatase 1
2010 Leone, V; Mansueto, G; Pierantoni, Gm; Tornincasa, M; Merolla, F; Cerrato, A; Santoro, M; Grieco, M; Scaloni, A; Celetti, A; Fusco, A
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.
2009 Bleeker, Fe; Lamba, S; Leenstra, S; Troost, D; Hulsebos, T; Vandertop, Wp; Frattini, M; Molinari, F; Knowles, M; Cerrato, A; Rodolfo, M; Scarpa, A; Felicioni, L; Buttitta, F; Malatesta, S; Marchetti, A; Bardelli, A
Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets
2009 Cerrato, A; De Falco, V; Santoro, M
Genetic interactions between Drosophila melanogaster menin and Jun/Fos.
2006 Cerrato, A; Parisi, M; Santa Anna, S; Missirlis, F; Guru, S; Agarwal, S; Sturgill, D; Talbot, T; Spiegel, A; Collins, F; Chandrasekharappa, S; Marx, S; Oliver, B
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Editorial: Combinatorial Approaches for Cancer Treatment: From Basic to Translational Research | 1-gen-2022 | Aniello Cerrato; George Mattheolabakis; Daniela Spano | |
| Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma | 1-gen-2019 | Morra, F; Merolla, F; D'Abbiero, D; Ilardi, G; Campione, S; Monaco, R; Guggino, G; Ambrosio, F; Staibano, S; Cerrato, A; Visconti, R; Celetti, A | |
| CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis 06 Biological Sciences 0601 Biochemistry and Cell Biology | 1-gen-2019 | Morra F.; Merolla F.; Criscuolo D.; Insabato L.; Giannella R.; Ilardi G.; Cerrato A.; Visconti R.; Staibano S.; Celetti A. | |
| Identification of novel biomarkers of homologous recombination defect in DNA repair to predict sensitivity of prostate cancer cells to PARP-inhibitors | 1-gen-2019 | Criscuolo D.; Morra F.; Giannella R.; Cerrato A.; Celetti A. | |
| New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment | 1-gen-2019 | Criscuolo D.; Morra F.; Giannella R.; Visconti R.; Cerrato A.; Celetti A. | |
| NSCLC Mutated Isoforms of CCDC6 Affect the Intracellular Distribution of the Wild Type Protein Promoting Cisplatinum Resistance and PARP Inhibitors Sensitivity in Lung Cancer Cells. | 1-gen-2019 | Cerrato A; Morra F; Di Domenico I; Celetti A. | |
| The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer | 1-gen-2018 | Cerrato, Aniello; Visconti, Roberta; Celetti, Angela | |
| CCDC6: The identity of a protein known to be partner in fusion | 1-gen-2017 | Cerrato A.; Merolla F.; Morra F.; Celetti A. | |
| The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells. | 1-gen-2017 | Morra, Francesco; Merolla, Francesco; Napolitano, Virginia; Ilardi, Gennaro; Miro, Caterina; Paladino, Simona; Staibano, Stefania; Cerrato, Aniello; Celetti, Angela | |
| USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs | 1-gen-2017 | Malapelle U.; Morra F.; Ilardi G.; Visconti R.; Merolla F.; Cerrato A.; Napolitano V.; Monaco R.; Guggino G.; Monaco G.; Staibano S.; Troncone G.; Celetti A. | |
| Wnt/Tcf1 pathway restricts embryonic stem cell cycle through activation of the Ink4/Arf locus | 1-gen-2017 | De JaimeSoguero, A; Aulicino, F; Ertaylan, G; Griego, A; Cerrato, A; Tallam, A; del Sol, A; Cosma, Mp; Lluis, F | |
| Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: The rationale for their inclusion in the clinic | 1-gen-2016 | Cerrato, A; Morra, F; Celetti, A | |
| FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC. | 1-gen-2015 | Morra, F; Luise, C; Merolla, F; Poser, I; Visconti, R; Inuzuka, H; Ilardi, G; Guggino, G; Monaco, R; Colecchia, D; Monaco, G; Cerrato, A; Chiariello, M; Denning, Krista; Paolo Claudio, Pier; Staibano, S; Celetti, A | |
| New therapeutic perspectives in CCDC6 deficient lung cancer cells | 1-gen-2015 | Morra F.; Luise C.; Visconti R.; Staibano S.; Merolla F.; Ilardi G.; Guggino G.; Paladino S.; Sarnataro D.; Franco R.; Monaco R.; Zitomarino F.; Pacelli R.; Monaco G.; Rocco G.; Cerrato A.; Linardopoulos S.; Muller M.T.; Celetti A. | |
| New therapeutic perspectives in CCDC6 deficient lung cancer cells. | 1-gen-2014 | Morra F; Luise C; Visconti R; Staibano S; Merolla F; Ilardi G; Guggino G; Paladino S; Sarnataro D; Franco R; Monaco R; Zitomarino F; Pacelli R; Monaco G; Rocco G; Cerrato A; Linardopoulos S; Muller MT; Celetti A. | |
| Chromatin and DNA methylation dynamics during retinoic acid-induced RET gene transcriptional activation in neuroblastoma cells. | 1-gen-2011 | Angrisano, T; Sacchetti, S; Natale, F; Cerrato, A; Pero, R; Keller, S; Peluso, S; Perillo, B; Avvedimento, Ve; Fusco, A; Bruni, Cb; Lembo, F; Santoro, M; Chiariotti, L | |
| CCDC6 represses CREB1 activity by recruiting histone deacetylase 1 and protein phosphatase 1 | 1-gen-2010 | Leone, V; Mansueto, G; Pierantoni, Gm; Tornincasa, M; Merolla, F; Cerrato, A; Santoro, M; Grieco, M; Scaloni, A; Celetti, A; Fusco, A | |
| IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. | 1-gen-2009 | Bleeker, Fe; Lamba, S; Leenstra, S; Troost, D; Hulsebos, T; Vandertop, Wp; Frattini, M; Molinari, F; Knowles, M; Cerrato, A; Rodolfo, M; Scarpa, A; Felicioni, L; Buttitta, F; Malatesta, S; Marchetti, A; Bardelli, A | |
| Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets | 1-gen-2009 | Cerrato, A; De Falco, V; Santoro, M | |
| Genetic interactions between Drosophila melanogaster menin and Jun/Fos. | 1-gen-2006 | Cerrato, A; Parisi, M; Santa Anna, S; Missirlis, F; Guru, S; Agarwal, S; Sturgill, D; Talbot, T; Spiegel, A; Collins, F; Chandrasekharappa, S; Marx, S; Oliver, B |